source
- Iopofosine I-131 shows high response rates and durable disease control in Waldenstrom macroglobulinemia trialThe 12‑month follow‑up from the CLOVER‑WaM study reports that patients receiving Iopofosine I‑131 achieved strong clinical activity in Waldenstrom macroglobulinemia. In the per‑protocol group, the…
- Cytokinetics’ Myqorzo hits twin efficacy targets in genetic heart disease trial, while Viridian reports positive Phase 3 data for elegrobartCytokinetics announced that its experimental heart‑failure drug Myqorzo achieved both primary efficacy endpoints in a study of patients with genetic cardiomyopathy, showing significant symptom impr…STAT · 4mo agoPositive readoutPositive